Biotech · Private company
InflaRx GmbH
Track this companyFree. Adds InflaRx GmbH to your Dealase workspace and tells you when its record changes.
Clinical trials104 recruiting or active
Pipeline programs12From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline12
- vilobelimabPhase 3 · Pyoderma GangrenosumClinicalTrials.gov · fetched Nov 12, 2026
- CSU high dose treatmentPhase 2 · Chronic Urticaria, IdiopathicClinicalTrials.gov · fetched Nov 12, 2026
- CSU lower dose treatmentPhase 2 · Chronic Urticaria, IdiopathicClinicalTrials.gov · fetched Nov 12, 2026
- CSU non responders IgE - high dose treatmentPhase 2 · Chronic Urticaria, IdiopathicClinicalTrials.gov · fetched Nov 12, 2026
- HS high dose treatmentPhase 2 · Chronic Urticaria, IdiopathicClinicalTrials.gov · fetched Nov 12, 2026
- HS low dose treatmentPhase 2 · Chronic Urticaria, IdiopathicClinicalTrials.gov · fetched Nov 12, 2026
- HS medium dose treatmentPhase 2 · Chronic Urticaria, IdiopathicClinicalTrials.gov · fetched Nov 12, 2026
- IFX-1Phase 2 · Hidradenitis Suppurativa (HS)ClinicalTrials.gov · fetched Nov 12, 2026
- IFX-1 high dosePhase 2 · Granulomatosis With Polyangiitis (GPA)ClinicalTrials.gov · fetched Nov 12, 2026
- IFX-1 low dosePhase 2 · Granulomatosis With Polyangiitis (GPA)ClinicalTrials.gov · fetched Nov 12, 2026
- VilobelimabPhase 2 · SCC - Squamous Cell Carcinoma of SkinClinicalTrials.gov · fetched Nov 12, 2026
- Vilobelimab + pembrolizumab combination therapyPhase 2 · SCC - Squamous Cell Carcinoma of SkinClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: BevacizumabPHASE2 · RECRUITING · started Oct 28, 2025ClinicalTrials.gov NCT06701656 · fetched Nov 12, 2026
- JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: VilobelimabPHASE2 · RECRUITING · started Jun 21, 2025ClinicalTrials.gov NCT06701682 · fetched Nov 12, 2026
- JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: ParidiprubartPHASE2 · RECRUITING · started Jun 10, 2025ClinicalTrials.gov NCT06701669 · fetched Nov 12, 2026
- JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)PHASE2 · RECRUITING · started Jun 10, 2025ClinicalTrials.gov NCT06703073 · fetched Nov 12, 2026
- Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis SuppurativaPHASE2 · TERMINATED · started Jan 2, 2025ClinicalTrials.gov NCT06555328 · fetched Nov 12, 2026
- Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma GangrenosumPHASE3 · TERMINATED · started Nov 1, 2023ClinicalTrials.gov NCT05964413 · fetched Nov 12, 2026
- Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.PHASE2 · TERMINATED · started Mar 31, 2021ClinicalTrials.gov NCT04812535 · fetched Nov 12, 2026
- Exploratory Study of IFX-1 in Patients With Pyoderma GangrenosumPHASE2 · COMPLETED · started May 16, 2019ClinicalTrials.gov NCT03971643 · fetched Nov 12, 2026
- Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPAPHASE2 · TERMINATED · started Oct 15, 2018ClinicalTrials.gov NCT03712345 · fetched Nov 12, 2026
- Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)PHASE2 · COMPLETED · started Feb 26, 2018ClinicalTrials.gov NCT03487276 · fetched Nov 12, 2026